Omeros to Present at 2024 EHA Hybrid Congress

SEATTLE – Omeros Corporation has revealed that data from an interim analysis of its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria (PNH) has been selected for a podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress. The event is scheduled to take place from June 13-16, 2024, in Madrid, Spain. OMS906 is an investigational inhibitor of MASP-3, aimed at targeting the alternative pathway of complement in the immune system. Alongside the podium presentation, two additional poster presentations on OMS906 will also be featured at the congress.

The abstracts for the presentations will be published on May 14, 2024, and will be accessible on the EHA website. Below are the details of the congress presentations:

1. OMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)
- Session Name: s454 Clinical and translational in bone marrow failure syndromes and PNH
- Date: Saturday, June 15, 2024
- Podium Presentation Session Time: 4:30 p.m. CEST
- Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102
- Presenting Author: Morag Griffin MBChB, FRCPath

2. Clinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)
- Date: Friday, June 14, 2024
- Presentation Time: 6:00 p.m. - 7:00 p.m. CEST
- Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7
- Presenting Author: William Pullman MB BS, PhD, FRACP

3. Exposure-Response Modeling Using Population PK/PD Methods Reliably Predict Population and Individual Responses of Complement Mature Factor D, Hemoglobin and LDH in PNH Patients Exposed to OMS906 (Abstract #P1920)
- Date: Friday, June 14, 2024
- Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7
- Presenting Author: William Pullman MB BS, PhD, FRACP

Presentation materials associated with each abstract will be available on Omeros’ website following the congress presentations.

About OMS906
OMS906 is an investigational humanized monoclonal antibody that targets mannan-binding lectin-associated serine protease-3 (MASP-3), a key activator of the complement system’s alternative pathway. The complement system is crucial in inflammation, activated by tissue damage or microbial infection. MASP-3 is responsible for converting pro-complement factor D to complement factor D, making it an essential target in the alternative pathway due to its low circulating levels and relative clearance compared to other pathway proteins. Unlike C5 and C3 blockers, MASP-3 inhibition preserves the lytic arm of the classical pathway, which is vital for infection defense. Furthermore, MASP-3 is not considered an acute phase reactant, offering potential advantages over other alternative pathway inhibitors. MASP-3 inhibitors like OMS906 may have therapeutic effects across various diseases, including PNH, hemolytic uremic syndrome (HUS), traumatic brain injury, arthritis, and other immune-related disorders.

About Omeros Corporation
Omeros Corporation is a pioneering biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for both large-market and orphan indications, particularly targeting immunologic disorders like complement-mediated diseases. The company’s lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is under review by the FDA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. OMS1029, a long-acting MASP-2 inhibitor, is in a Phase 1 clinical trial. OMS906, targeting MASP-3, is progressing towards Phase 3 trials for PNH and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ OMS527 is in development for treating cocaine use disorder and other addictions, as well as complications from treatment for movement disorders. Additionally, Omeros is advancing a portfolio of novel immuno-oncology programs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!